IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plication of: Meade et al.

Serial No.:

09/012,904

Group No.:

1636

Filed:

01/23/1998

Examiner:

Celine X. Qian

For:

Transgenic Production of Antibodies in Milk

Attorney Docket Number:

GTC-1 D3

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT AFTER THE FIRST OFFICE ACTION ON THE MERITS BUT BEFORE MAILING OF EITHER A FINAL ACTION OR A NOTICE OF ALLOWANCE (37 CFR 1.97(c))

Authority ≒1.

Pursuant to 37 CFR § § 1.56 and 1.97-1.99, the Applicant cites to the Examiner documents containing information which, in good-faith judgment of the Applicant, may be relevant to the subject mater claimed in the above-identified application. The Applicant also encloses copies of the Englishlanguage cited documents.

In submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that a search has been performed, or the extent of any search performed, or that more relevant information does not exist. Applicant does note that its representation before the USPTO has recently changed.

In submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that any document cited in this Supplemental Information Disclosure Statement is, or is considered to be prior art as defined by 35 USC § § 102 and 103.

2. Time of transmittal of accompanying Supplemental Information Disclosure Statement

The Supplemental Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of this application and after the mailing date of the first Office action on the merits, but before the mailing date of either:

- (1) a final action under § 1.113, or
- (2) a notice of allowance under § 1.311, whichever occurs first.

33/10/2004 CNGUYÉN 00000146 502092 80.00 DA

CERTIFICATE OF MAILING BY EXPRESS MAIL I hereby certify that under 37 CFR §1.10 that this correspondence is being deposited on March with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage in an envelope addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kristin Kaberry

3. Amount of Fee

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Supplemental Information Disclosure Statement under § 1.97(c).

Fee due \$ 180.00

4. Authority to charge Deposit Account

Please charge this \$180.00 and any other necessary fees which may be required during the entire pendency of this application to Deposit Account No. 502092. A duplicate of this transmittal is enclosed for this purpose.

5. Foreign Search Reports

A copy of the PCT International Search Report from a counterpart application is enclosed. Legible copies of all items listed in Form PTO-1449 accompany this information statement. Cumulative patents or publications identified in the attached PCT Search Report are not enclosed.

The Applicant respectfully requests that:

- a. The Examiner consider the cited information in reaching a determination concerning the patentability of the pending claims; and
- b. The enclosed Form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

The person making this statement is the attorney who signs below on the basis of the

information in the attorney's file.

Dated:

By:

Byron V. Olsen, Reg. No. 42,960

Attorney for Applicant

GTC Biotherapeutics, Inc.

175 Crossing Blvd., Suite 410

Framingham, MA 01702

Tel. #(508) 370-5150 Fax #(508) 370-3797

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	09/012,904		
Filing Date	01/23/1998		
First Named Inventor	Harry M. Meade		
Art Unit	1636		
Examiner Name	Celine X. Qian		
Attorney Docket Number	GTC-1 D3		

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (# known)}			Figures Appear
		US-			
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			
		US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶	
		EP 0 279 582 A	08-24-1988	Baylor College			
		WO 91 08216 A	06-13-1991	GenPharm			
						L	
	ļ					L	
						L	
					*		

Examiner	Date	
Signature	Considered	
		l

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Include copy of this form with next communication to applicant, Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Include copy of the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1405016			e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Substitute for formal party			Application Number	09/012,904	
INFORMATION	DIS	CLOSURE	Filing Date	01/23/1998	
STATEMENT BY APPLICANT			First Named Inventor	Harry M. Meade	
(Use as many sheets as necessary)			Art Unit	1636	
Ose as many snee	13 d3 116	icessary)	Examiner Name	Celine X. Qian	
Sheet 2	of	2	Attorney Docket Number	GTC-1 D3	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title the item (book, magazine, journal, serial, symposium, canumber(s), publisher, city and/or cour	talog, etc.), date,	page(s), volume-issue	T ²
		YOM et al., Genetic Engineering of Milk Composition Lactating Transgenic Animals, Am J Clin Nutr, 19	n: Modification 193: 58, pgs. 29	of Milk Components 9S-306S.	
				-	
		·			
		·			
			-		
Examiner	Ţ		Date		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.